SCHEMBL3011364

SCHEMBL3011364

CC(C)c1cc(C(C)C)c(S(=O)(=O)N2CCN(c3nc(Cc4ccc(Cl)c(Cl)c4)cs3)CC2)c(C(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
DPP8 Q6V1X1 1/20 0.38
THRB P10828 1/20 0.37
FABP4 P15090 2/20 0.37
ALDH1A1 P00352 2/20 0.37
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
AR P10275 1/20 0.36
MEN1 O00255 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
FPR2 P25090 3/20 0.36
PROKR1 Q8TCW9 3/20 0.36
EPHX2 P34913 1/20 0.36
OGA O60502 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
HTR6 P50406 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3654029 0.95 FABP4 (0.36) LMNAL3MBTL1DPP8THRBFABP4
SCHEMBL3008045 0.92 CACNA1G (0.39) LMNAL3MBTL1DPP8FABP4ALDH1A1
SCHEMBL3014217 0.92 CACNA1G (0.39) LMNAL3MBTL1DPP8FABP4ALDH1A1
SCHEMBL3006975 0.92 FABP4 (0.42) LMNAL3MBTL1DPP8FABP4ALDH1A1
SCHEMBL3011840 0.89 ALDH1A1 (0.39) LMNAL3MBTL1DPP8FABP4ALDH1A1
SCHEMBL3650838 0.89 FABP4 (0.38) LMNAL3MBTL1DPP8FABP4ALDH1A1
SCHEMBL3013519 0.89 OGA (0.39) LMNAL3MBTL1DPP8THRBFABP4
SCHEMBL3018377 0.89 ALDH1A1 (0.40) LMNAL3MBTL1DPP8FABP4ALDH1A1
SCHEMBL3013070 0.88 CACNA1G (0.44) LMNAL3MBTL1DPP8FABP4ALDH1A1
SCHEMBL3015626 0.88 MEN1 (0.44) LMNAL3MBTL1DPP8ALDH1A1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885L3MBTL1 1847/4885DPP8 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.